Press releases

31 July 2020 Regulatory

First patient treated in Stayble’s clinical phase 2b study

Stayble Therapeutics announces today, July 31, 2020, that the first patient has been treated in Stayble’s clinical phase 2b study. STA363 is targeting patients suffering from chronic low back pain c...

02 July 2020

Stayble’s clinical phase 2b study has now also started in the Netherlands

Stayble announces today, July 2, 2020, that the Company has initiated the first clinic in the Netherlands and now recruiting patients. The company has previously initiated clinics in Russia. STA363 is...

16 June 2020 Regulatory

Stayble’s clinical phase 2b study has started

Stayble announces today, June 16, 2020, that the Company´s clinical phase 2b study with STA363 has started with the first clinic in Russia being initiated and now recruiting patients. STA363 is targe...

08 June 2020 Regulatory

Report from the annual general meeting of Stayble Therapeutics on June 8, 2020

Today, June 8, 2020, the annual general meeting of Stayble Therapeutics AB was held. Below is a summary of the resolutions made. All resolutions were passed with the required majority....

20 May 2020 Regulatory

Stayble receives approval from regulatory authorities to start clinical phase 2b study with STA363 in Russia

Stayble announces today, May 20, 2020, that the Russian regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The Company has previ...

01 May 2020 Regulatory

Stayble receives approval from regulatory authorities to start clinical phase 2b study in Spain

Stayble announces today, May 1, 2020, that the Spanish regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The Company has previo...

21 April 2020 Regulatory

Stayble publishes the Annual Report for 2019

Gothenburg, April 21, 2020 – Stayble Therapeutics, today announced the publication of the Annual Report 2019....

14 April 2020

Stayble has, together with APL, completed manufacturing of the investigational drug for the upcoming clinical phase 2b study.

The Company announces that the investigational drug (two doses of STA363 and placebo) now is manufactured and quality assured by our partner APL....

17 March 2020 Regulatory

Stayble receives approval from regulatory authorities to start clinical phase 2b study in The Netherlands

Stayble announces today, March 17 2020, that the Dutch regulatory authorities (RA) have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The approval from...

17 March 2020

Stayble has submitted applications to regulatory authorities in Spain for start of the Phase 2b clinical trial.

The company can announce that an additional important step for starting the phase 2b clinical trial during Q2 has been completed. The company has submitted applications to regulatory authorities in Sp...

09 March 2020

Stayble has submitted applications to regulatory authorities in The Netherlands for start of the Phase 2b clinical trial.

The company can announce that an important step for starting the phase 2b clinical trial during Q2 has been completed. The company has submitted applications to regulatory authorities and ethical comm...

09 March 2020

The trade in Stayble’s shares and warrants on Nasdaq First North Growth Markets commences today

Today, March 9 2020, marks the first day of trading in Stayble Therapeutics AB’s (“Stayble” or “the Company”) shares and warrants on Nasdaq First North Growth Market. The share is traded und...

06 March 2020

Stayble appoints Mangold as Liquidity Provider

Stayble Therapeutics AB (”Stayble” or the “Company”) has appointed Mangold Fondkommission as liquidity provider for the Company's share on Nasdaq First North Growth Market with first day of tr...

04 March 2020 Regulatory

Stayble has been approved for listing on Nasdaq First North Growth Market with first day of trading March 9, 2020

Nasdaq Stockholm AB has approved Stayble Therapeutics AB’s (”Stayble” or ”the Company”) application for listing of the Company’s shares and warrants of series TO1 on Nasdaq First North Gro...

21 February 2020

Stayble’s new issue was subscribed to 436%

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMB...

17 February 2020

Tomorrow is the last day of subscription for Stayble’s new issue in connection to the intended listing on Nasdaq First North Growth Market

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMB...

04 February 2020

The subscription period for Stayble’s new issue in connection to the intended listing on Nasdaq First North Growth Market begins today and the Company invites to investment events

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMB...

31 January 2020

Stayble Therapeutics AB publishes prospectus relating to the issuance of units in connection with the intended listing on Nasdaq First North Growth Market

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMB...

30 January 2020

Stayble Therapeutics AB intends to be listed on Nasdaq First North Growth Market and carries out a new issue in connection to the listing

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMB...

31 July 2020 Regulatory

First patient treated in Stayble’s clinical phase 2b study

Stayble Therapeutics announces today, July 31, 2020, that the first patient has been treated in Stayble’s clinical phase 2b study. STA363 is targeting patients suffering from chronic low back pain c...

16 June 2020 Regulatory

Stayble’s clinical phase 2b study has started

Stayble announces today, June 16, 2020, that the Company´s clinical phase 2b study with STA363 has started with the first clinic in Russia being initiated and now recruiting patients. STA363 is targe...

08 June 2020 Regulatory

Report from the annual general meeting of Stayble Therapeutics on June 8, 2020

Today, June 8, 2020, the annual general meeting of Stayble Therapeutics AB was held. Below is a summary of the resolutions made. All resolutions were passed with the required majority....

20 May 2020 Regulatory

Stayble receives approval from regulatory authorities to start clinical phase 2b study with STA363 in Russia

Stayble announces today, May 20, 2020, that the Russian regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The Company has previ...

01 May 2020 Regulatory

Stayble receives approval from regulatory authorities to start clinical phase 2b study in Spain

Stayble announces today, May 1, 2020, that the Spanish regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The Company has previo...

21 April 2020 Regulatory

Stayble publishes the Annual Report for 2019

Gothenburg, April 21, 2020 – Stayble Therapeutics, today announced the publication of the Annual Report 2019....

17 March 2020 Regulatory

Stayble receives approval from regulatory authorities to start clinical phase 2b study in The Netherlands

Stayble announces today, March 17 2020, that the Dutch regulatory authorities (RA) have approved the Company´s clinical trial application on the clinical phase 2b study with STA363. The approval from...

04 March 2020 Regulatory

Stayble has been approved for listing on Nasdaq First North Growth Market with first day of trading March 9, 2020

Nasdaq Stockholm AB has approved Stayble Therapeutics AB’s (”Stayble” or ”the Company”) application for listing of the Company’s shares and warrants of series TO1 on Nasdaq First North Gro...